Mankind to expand gastro, derma presence, says MD Rajeev Juneja

Copyright © HT Digital Streams Limit all rights reserved. Jessica Jani 5 min read May 27, 2025, 07:03 PM IST Humanity develops a new medicine against the obesity and diabetes in the home. (Reuters) Summary The pharmaceutical enterprise evaluates all options to increase its presence in therapy areas, including products in licensing of innovators or to make a small acquisition, Juneja said. Mankind Pharma is focused on expanding his presence in the gastro -intestinal and dermatological segments this year, as he looks at the expansion of his presence in the chronic segments, managing director Rajeev Juneja said. “We are not good at the gastro [segment]… We have decided that we are supposed to work a lot in gastro because it has become semi-chronic, and our tendency is to the chronic side, “Juneja said, adding that Gastro in India is one of the fastest growing segments.” In addition, we work on Derma, “he said. Anti-O-OBsity and Diabetes Drug In-House. Sun Pharma to increase growth in the growth in the FY26 Juneja, said that the company evaluates all options to increase its presence in these therapy areas, including products in licensing of innovators or small acquisitions. Juneja. ‘ The point is that once we decide that we plan to be supposed to be good at the gastro -side, we start looking for roads, we start looking for people, we will begin to strengthen his leadership in the female health segment, which has received a boost over the past year by the acquisition of the Barat serum and vaccines, which has received a boost of the annual. Future, because we have seen that once you create a kind of brand, it is a very large access barrier, ‘he added. acquisition, and it is the company that is acquiring the acquisition, and it is the company that is acquiring the acquisition, and it is the company that is acquiring the acquisition, and it is the company that is acquiring the acquisition, and it has focused on obtaining the company acquisition. -Arpares at Systematix Group, the BSV’s platform and skills degree for making recombinant medicines (created by placing genes of one species in a host species), which put the bio -bio -process in the bag. , “Juneja said.” We started our own R&D in humanity. On the domestic side, “Juneja said, adding that” we must have certain innovative products, and we work for it “. The focus of humanity on innovation and specialty segments comes as the Indian pharmaceutical market became more pressure. Most segments have established all market leaders.” … The promoters realize that there is a challenge for growth. And they know that the space they played in is now difficult to expand from where they are, and expands meaningfully where they are. So I think that humanity promoters are very committed to India matters, they are also prepared for how to take it forward, “Manchanda said.” What they are actually looking for is a bigger way to build up growth, “he added to humanity’s BSV acquisition. Internal correction man has undertaken several internal correction initiatives. On vaccines and Medech, “When you look at the history of humanity, we have become the fourth largest company,” Juneja said, adding that for any business that grows very quickly, there is a time when growth platoes are. “But once you bring commercial excellence, you can come a number of mistakes and your profits and profits, whether it is a cover, to remove it immediately,” Juneja said. ” We belong to the second category, and we have decided that by March 2025 we will clean up humanity from all sides, “he added. Catch all the corporate news and updates on live currency. Download the Mint News app to get Daily Market Updates & Live Business News. More Topics #Mankind Pharma Read Next Story